Research from National Library of Medicine in 2024 also suggests GLP-1 drugs are linked to adverse gastrointestinal events, including nausea, vomiting, delayed gastric emptying and pancreatitis
[10] SURMOUNT-1 : Tirzepatide for the treatment of obesity produced ~2022% weight loss over 72 weeks, among the largest effects seen in pharmacologic obesity treatment
One batch
Microdosing is considered off-label use, or prescribing an approved drug for an unapproved use, which doctors are allowed to do if they deem it medically appropriate
There is a holistic interplay between hormones, neurotransmitters, gut bacteria, immune function, breathing, diet, exercise and more
No matter the dose, people on orforglipron lost more weight and saw a greater reduction in blood sugar than people on placebo, the study found